XPO1 and non-small cell lung carcinoma: In lung cancer xenograft models, XPO1 inhibition interfered with NE transformation by downregulating SOX2, a key driver of NSCLC-to-SCLC lineage plasticity, thereby prolonging the efficacy of targeted therapies and supporting XPO1 inhibition as a strategy to constrain NE reprogramming [78].